Studi In Silico Senyawa Daun Sirsak (Annona muricata L.) Sebagai Inhibitor BRAF V600E Pada Kanker Melanoma
##plugins.pubIds.doi.readerDisplayName##
https://doi.org/10.24843/JFU.2022.v11.i02.p07
Abstrak
Kanker melanoma merupakan sebuah keganasan yang terjadi pada sel melanosit. Karakteristik dari kanker ini yaitu tonjolan dan warna yang tidak beraturan pada kulit. Pengobatan yang digunakan saat ini salah satunya adalah agen kemoterapi vemurafenib. Seperti yang telah diketahui, agen kemoterapi dapat menyebabkan berbagai efek samping pada tubuh. Oleh karena itu, dilakukan pencarian senyawa lain yang berpotensi dan menghasilkan efek samping lebih sedikit. Penelitian ini dilakukan dengan pendekatan in silico yaitu penambatan molekuler. Dilakukan juga prediksi terhadap profil farmakokinetik menggunakan aturan Lipinski dan PreADMET. Senyawa dari daun tanaman sirsak (Annona muricata L.) diketahui memiliki potensi untuk menghambat aktivitas pembelahan sel melalui interaksi dengan reseptor BRAF V600E. Reticuline diketahui memiliki nilai energi Gibbs sebesar -8,78; nilai konstanta inhibisi sebesar 395.39 nM; dan berikatan pada asam amino
##plugins.generic.usageStats.downloads##
##plugins.generic.usageStats.noStats##
Referensi
Ali, Z., Yousaf, N., & Larkin, J. (2013). Melanoma epidemiology, biology and prognosis. EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer. 11(2), 81–91. https://doi.org/10.1016/j.ejcsup.2013.07.012
American Cancer Society. (2019). Chemotherapy for Melanoma Skin Cancer. https://www.cancer.org/cancer/melanoma-skin-cancer/treating/chemotherapy.html#references
Doak, B.C., Over, B., Giordanetto, F., dan Kihlberg, J. (2014). Oral Druggable Spade Beyond The Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry & Biology, 21 (9), 1115-1142. https://doi.org/10.1016/j.chembiol.2014.08.013
Goodwin, R.J.A., Bunch, J., dan McGinnity, D.F. 2017. Mass Spectrometry Imaging in Oncology Drug Discovery. Advances in Cancer Research, 134, 133-171. https://doi.org/10.1016/bs.acr.2016.11.005
Khaddour, K., Kurn, H., dan Zito, P.M. (2022). Vemurafenib. https://www.ncbi.nlm.nih.gov/books/NBK535429/
Kilo, A.L., Aman, L. O., Sabihi, I., dan Kilo, J.L. (2019). Studi Potensi Pirazolin Tersubstitusi 1-N dari Tiosemikarbazon sebagai Agen Antimuba Melalui Uji in silico. Indo. J. Chem. Res., 7 (1), 9-16. https://ojs3.unpatti.ac.id/index.php/ijcr/article/view/725
Kumar, R., Giri, A., Nadendla, R. R. (2018). In Silico ADME Profiling Of CDK9 Inhibitors. Journal of Scientific Research in Pharmacy. 7(3): 30-34. https://doi.org/10.5281/zenodo.1207094
Lestari, T. 2015. Studi Interaksi Senyawa Turunan 1,3- Dibenzoiltiourea sebagai Ribonukleotida Reduktase Inhibitor. Jurnal Farmasi Indonesia. Vol. 7: 163–169
Ma, C. & Armstrong, A. W. (2013). Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. Journal of Dermatological Treatment, 25(5), 401–408. https://doi.org/10.3109/09546634.2013.813897
Mustika, D.N.,dan Fakih, T.M., Aprilia, H. 2021. Uji In-Silico Aktivitas Melanogenesis Senyawa Turunan Betacyanin Buah Naga Merah (Hylocereus Polyhizuz) sebagai Inhibitor Enzim Tirosinase. Prosiding Farmasi, 7(2): 443-446. https://karyailmiah.unisba.ac.id/index.php/farmasi/article/view/29391/
National Cancer Institute. (2021). Melanoma Treatment. https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq
Nurgali, K., Jagoe, R. T., & Abalo, R. (2018). Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?. Frontiers in pharmacology, 9, 245. https://doi.org/10.3389/fphar.2018.00245
Ott PA.(2019). Intralesional Cancer Immunotherapies. Hematol Oncol Clin North Am, 33(2), 249-260. https://doi.org/10.1016/j.hoc.2018.12.009
Pratama, A.A., Rifai, Y., Marzuki,A. (2017). Docking Molekuler Senyawa 5,5’-Dibromometilsesamin. Majalah Farmasi dan Farmakologi, 21(3), 67-69. https://doi.org/10.20956/mff.v21i3.6857
Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Salgado, J., & Ruiz-Frutos, C. (2020). Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine, 99(33), 21695. https://doi.org/10.1097/MD.0000000000021695
Saginala, K.,Barsouk, A., Aluru, J.S., Rawla, P., Barsouk,A. (2021). Epidemiology of Melanoma. Medical Science, 9(4), 63. https://doi.org/10.3390%2Fmedsci9040063
Santarpia, L., Lippman, S.L., dan El-Naggar, A. 2012. Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy. Expert Opinion in Theurapeutic Targets, 16(1), 113-119. https://doi.org/10.1517/14728222.2011.645805
Siswarni, M., Nurhayani., Sinaga, S. 2016. Ekstraksi asetogenin dari daun dan biji Sirsak (Annona muricata L.) dengan Pelarut Aseton. Jurnal Teknik Kimia USU, 5(2), 1-4. https://doi.org/10.32734/jtk.v5i2.1533
Syakir, M. A. dan Anggraini, D. I. (2020). Terapi Imunologi Pada Melanoma. Jurnal Ilmiah Kedokteran Indonesia, 8(2), 103–110. https://doi.org/10.53366/jimki.v8i2.118
Syahputra, B., Ambarsari, L., dan Sumaryada, T. (2014). Simulasi Docking Kurkumin Enol, Bisdemetoksikurkumin dan Analognya sebagai Inhibitor Enzim 12-Lipooksigenase. Jurnal Biofisika, 10(1): 55-67. https://journal.ipb.ac.id/index.php/biofisika/article/view/9354/7334
Tarhini A, Atzinger C, Gupte-Singh K, Johnson C, Macahilig C, Rao S. (2019). Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. J Comp Eff Res, 8(7), 461-473. https://doi.org/10.2217/cer-2019-0003
WHO. (2022). Cancer pada Mei 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
Wahab, S.M.A., Jantan, I., Haque, Md.A., dan Arshad, L. 2018. Exploring the Leaves of Annona muricata L. as a Source of Potential Anti-inflammatory and Anticancer Agents. Frontiers in Pharmacology, 9(661), 1-20. https://doi.org/10.3389%2Ffphar.2018.00661
American Cancer Society. (2019). Chemotherapy for Melanoma Skin Cancer. https://www.cancer.org/cancer/melanoma-skin-cancer/treating/chemotherapy.html#references
Doak, B.C., Over, B., Giordanetto, F., dan Kihlberg, J. (2014). Oral Druggable Spade Beyond The Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry & Biology, 21 (9), 1115-1142. https://doi.org/10.1016/j.chembiol.2014.08.013
Goodwin, R.J.A., Bunch, J., dan McGinnity, D.F. 2017. Mass Spectrometry Imaging in Oncology Drug Discovery. Advances in Cancer Research, 134, 133-171. https://doi.org/10.1016/bs.acr.2016.11.005
Khaddour, K., Kurn, H., dan Zito, P.M. (2022). Vemurafenib. https://www.ncbi.nlm.nih.gov/books/NBK535429/
Kilo, A.L., Aman, L. O., Sabihi, I., dan Kilo, J.L. (2019). Studi Potensi Pirazolin Tersubstitusi 1-N dari Tiosemikarbazon sebagai Agen Antimuba Melalui Uji in silico. Indo. J. Chem. Res., 7 (1), 9-16. https://ojs3.unpatti.ac.id/index.php/ijcr/article/view/725
Kumar, R., Giri, A., Nadendla, R. R. (2018). In Silico ADME Profiling Of CDK9 Inhibitors. Journal of Scientific Research in Pharmacy. 7(3): 30-34. https://doi.org/10.5281/zenodo.1207094
Lestari, T. 2015. Studi Interaksi Senyawa Turunan 1,3- Dibenzoiltiourea sebagai Ribonukleotida Reduktase Inhibitor. Jurnal Farmasi Indonesia. Vol. 7: 163–169
Ma, C. & Armstrong, A. W. (2013). Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. Journal of Dermatological Treatment, 25(5), 401–408. https://doi.org/10.3109/09546634.2013.813897
Mustika, D.N.,dan Fakih, T.M., Aprilia, H. 2021. Uji In-Silico Aktivitas Melanogenesis Senyawa Turunan Betacyanin Buah Naga Merah (Hylocereus Polyhizuz) sebagai Inhibitor Enzim Tirosinase. Prosiding Farmasi, 7(2): 443-446. https://karyailmiah.unisba.ac.id/index.php/farmasi/article/view/29391/
National Cancer Institute. (2021). Melanoma Treatment. https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq
Nurgali, K., Jagoe, R. T., & Abalo, R. (2018). Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?. Frontiers in pharmacology, 9, 245. https://doi.org/10.3389/fphar.2018.00245
Ott PA.(2019). Intralesional Cancer Immunotherapies. Hematol Oncol Clin North Am, 33(2), 249-260. https://doi.org/10.1016/j.hoc.2018.12.009
Pratama, A.A., Rifai, Y., Marzuki,A. (2017). Docking Molekuler Senyawa 5,5’-Dibromometilsesamin. Majalah Farmasi dan Farmakologi, 21(3), 67-69. https://doi.org/10.20956/mff.v21i3.6857
Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Salgado, J., & Ruiz-Frutos, C. (2020). Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine, 99(33), 21695. https://doi.org/10.1097/MD.0000000000021695
Saginala, K.,Barsouk, A., Aluru, J.S., Rawla, P., Barsouk,A. (2021). Epidemiology of Melanoma. Medical Science, 9(4), 63. https://doi.org/10.3390%2Fmedsci9040063
Santarpia, L., Lippman, S.L., dan El-Naggar, A. 2012. Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy. Expert Opinion in Theurapeutic Targets, 16(1), 113-119. https://doi.org/10.1517/14728222.2011.645805
Siswarni, M., Nurhayani., Sinaga, S. 2016. Ekstraksi asetogenin dari daun dan biji Sirsak (Annona muricata L.) dengan Pelarut Aseton. Jurnal Teknik Kimia USU, 5(2), 1-4. https://doi.org/10.32734/jtk.v5i2.1533
Syakir, M. A. dan Anggraini, D. I. (2020). Terapi Imunologi Pada Melanoma. Jurnal Ilmiah Kedokteran Indonesia, 8(2), 103–110. https://doi.org/10.53366/jimki.v8i2.118
Syahputra, B., Ambarsari, L., dan Sumaryada, T. (2014). Simulasi Docking Kurkumin Enol, Bisdemetoksikurkumin dan Analognya sebagai Inhibitor Enzim 12-Lipooksigenase. Jurnal Biofisika, 10(1): 55-67. https://journal.ipb.ac.id/index.php/biofisika/article/view/9354/7334
Tarhini A, Atzinger C, Gupte-Singh K, Johnson C, Macahilig C, Rao S. (2019). Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. J Comp Eff Res, 8(7), 461-473. https://doi.org/10.2217/cer-2019-0003
WHO. (2022). Cancer pada Mei 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
Wahab, S.M.A., Jantan, I., Haque, Md.A., dan Arshad, L. 2018. Exploring the Leaves of Annona muricata L. as a Source of Potential Anti-inflammatory and Anticancer Agents. Frontiers in Pharmacology, 9(661), 1-20. https://doi.org/10.3389%2Ffphar.2018.00661
Diterbitkan
2023-01-31
##submission.howToCite##
DEWAYANI, Audry Rahma et al.
Studi In Silico Senyawa Daun Sirsak (Annona muricata L.) Sebagai Inhibitor BRAF V600E Pada Kanker Melanoma.
Jurnal Farmasi Udayana, [S.l.], p. 80-88, jan. 2023.
ISSN 2622-4607.
Tersedia pada: <https://ojs.unud.ac.id/index.php/jfu/article/view/88474>. Tanggal Akses: 15 oct. 2025
doi: https://doi.org/10.24843/JFU.2022.v11.i02.p07.
Terbitan
Bagian
Articles
